Boehringer offers 3T Biosciences $268M to plug its data into biotech's TCR cancer platform

09 Jan 2023
www.fiercebiotech.com
ImmunotherapyVaccineAcquisitionLicense out/in
Boehringer offers 3T Biosciences $268M to plug its data into biotech's TCR cancer platform
Preview
Source: FierceBiotech
Its deal with Boehringer Ingelheim is the first collaboration for 3T Biosciences, which exited stealth mode last August.
Boehringer Ingelheim wants to input its patient-derived T-cell receptor (TCR) data into 3T Biosciences' platform with the hope of identifying new antigen targets for cancer immunotherapies. If successful, 3T could be in line for a $268 million payday.
3T's platform is designed to combine wide-ranging target libraries with machine learning to improve the identification of novel shared TCR targets and screening of TCRs for specificity and off-target cross-reactivities. The ultimate goal: to produce tumor-specific, safer therapies that can be delivered at higher doses.
“3T's 3T-TRACE discovery platform has the potential to transform the treatment of cancers and beyond,” CEO Stefan Scherer, M.D., Ph.D., said in a Jan. 9 release. “By using data from patients for patients we aim to discover the best immunogenic targets for multiple tumor indications and across patient populations.”
Boehringer seems convinced, signing up to a collaboration that it says will accelerate and expand its own pipeline of T-cell based cancer therapies. In return, 3T will receive an undisclosed upfront payment and R&D support, with the possibility of discovery, preclinical, clinical, regulatory and commercial milestones reaching $268 million, on top of royalties.
The Boehringer deal is the first collaboration for 3T, which exited stealth mode last August. The Westlake Village BioPartners-backed biotech arrived on the scene armed with $40 million in series A cash, technology in-licensed from Stanford University and plans to advance a pipeline featuring development-stage TCR-T cell assets.
Recent progress at biotechs such as Adaptimmune and Immatics is beginning to validate the promise of TCR-based therapies, but, as 3T sees it, there remains scope for further improvements.
Meanwhile, Boehringer has had mixed success when it comes immuno-oncology. When the German Big Pharma acquired Texan biotech Abexxa Biologics in 2021, along with its T-cell receptor-like antibody to disrupt a specific immune checkpoint in oncology, it marked something of a rebound after a $600 million cancer mRNA vaccine pact with CureVac went up in smoke earlier in the year.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.